Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Rova-T had a convincing-looking mechanism of action, consisting of an antibody ... begin to bite into Humira in the US. The company said it will now focus on its other pipeline drugs, hoping ...

February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter 2024 earnings call. Bob Bradway will lead the call and be followed by a ...

In 2007, AstraZeneca’s pipeline was the subject of much speculation ... Having already acquired UK-based Cambridge Antibody Technology in 2006, AstraZeneca merged these two companies to create ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing ... Novartis removed one other drug from its pipeline this morning in the form of ...

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for ... of approved medicines and a promising pipeline, the company faces both significant ...

A Houston-based midstream energy company will go forward with its $1.7 billion natural gas pipeline that will be located right in the city's backyard. Kinder Morgan announced that the 216-mile ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

Click here to read more @ c-MET-NSCLC Pipeline Outlook JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs.